|
Real world experience of FGFR gene alterations and clinical outcomes in advanced/metastatic urothelial cancer in Japan: MONSTAR-SCREEN database study. |
|
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst) |
|
|
Honoraria - Ono Pharmaceutical; Takeda; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda |
Consulting or Advisory Role - Bayer |
Research Funding - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
|
Stock and Other Ownership Interests - Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Chugai Pharma; Eisai; Merck; MSD; Pfizer; Takeda |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; ONO PHARMACEUTICAL; Pfizer; Takeda |
Research Funding - Takeda |
|
|
Honoraria - Astellas Pharma; Janssen; Takeda |
Patents, Royalties, Other Intellectual Property - Shionogi |